. 2024 Apr 16;24:480. doi: 10.1186/s12885-024-12233-6

Table 1.

Baseline characteristics of the two group patients

Characteristics	HAIC-LEN-PD1 (n = 103)	LEN-PD1 (n = 61)	P
Gender Male Female	91 (88.3%) 12 (11.7%)	57 (93.4%) 4 (6.6%)	0.288
Age, years (median, SD)	52.0, 8.82	56.0, 7.88	0.115
ECOG score 0–1 2	96 (93.2%) 7 (6.8%)	58 (95.1%) 3 (4.9%)	0.627
BCLC B C	4 (3.8%) 99 (96.2%)	2 (3.3%) 59 (96.7%)	0.842
Child-Pugh A B	84 (81.6%) 19 (18.4%)	50 (82.0%) 11 (18.0%)	0.947
Viral status HBV others	93 (90.3%) 10 (9.7%)	58 (95.1%) 3 (4.9%)	0.272
Tumor size, cm (Mean) ≥ 10 cm < 10 cm	71 (68.9%) 32 (31.1%)	45 (73.8%) 16 (26.2%)	0.510
Portal vein invasion Absent VP1-2 VP3 VP4	9 (8.7%) 5 (4.9%) 19 (18.4%) 70 (68.0%)	4 (6.6%) 5 (8.2%) 9 (14.8%) 43 (70.4%)	0.882
Venous invasion Absent Present	76 (73.8%) 27 (26.2%)	50 (82%) 11 (18%)	0.230
Extrahepatic spread Absent Present	71 (68.9%) 32 (31.1%)	41 (67.2%) 20 (32.8%)	0.819
Tumor number Single Multiple	39 (37.9%) 64 (62.1%)	25 (41%) 36 (59%)	0.692
AFP, ng/ml(Mean) ≤ 400 > 400	33 (32.0%) 70 (68.0%)	26 (42.6%) 35 (57.4%)	0.172
High-risk type VP4 TO 50% Both	54 (52.4%) 33 (32.1%) 16 (15.5%)	31 (50.8%) 18 (29.5%) 12 (19.7%)	0.802
PD-1 inhibition agent Camrelizumab Tislelizumab Sintilimab	62 (60.2%) 26 (25.2%) 15 (14.6%)	32 (52.5%) 20 (32.8%) 9 (14.7%)	0.694
ALBI grade I II III	54 (52.4%) 47 (45.7%) 2 (1.9%)	25 (41.0%) 33 (54.1%) 3 (4.9%)	0.257
Laboratory tests TBil, µmol/L (Mean, SD) Albumin, g/L (Mean, SD) Platelet, ×109/L (Mean, SD) WBC, ×109/L (Mean, SD) PT, seconds (Mean, SD) Creatinine, µmol/L (Mean, SD) ALT, IU/L (Mean, SD) AST, IU/L (Mean, SD)	21.4, 12.3 38.4, 4.2 180.6, 78.6 6.0, 1.8 12.1, 1.1 65.5, 12.4 89.4, 55.9 58.1, 39.9	23.4, 14.4 39.3, 6.6 192.9, 86.6 6.4, 2.8 12.1, 1.1 75.0, 85.7 77.7, 38.6 49.9, 28.4	0.473 0.440 0.479 0.469 0.991 0.340 0.713 0.603

Characteristics

HAIC-LEN-PD1
(n = 103)

LEN-PD1
(n = 61)

Gender

Male

Female

91 (88.3%)

12 (11.7%)

57 (93.4%)

4 (6.6%)

0.288

Age, years (median, SD)

52.0, 8.82

56.0, 7.88

0.115

ECOG score

0–1

96 (93.2%)

7 (6.8%)

58 (95.1%)

3 (4.9%)

0.627

BCLC

4 (3.8%)

99 (96.2%)

2 (3.3%)

59 (96.7%)

0.842

Child-Pugh

84 (81.6%)

19 (18.4%)

50 (82.0%)

11 (18.0%)

0.947

Viral status

HBV

others

93 (90.3%)

10 (9.7%)

58 (95.1%)

3 (4.9%)

0.272

Tumor size, cm (Mean)

≥ 10 cm

< 10 cm

71 (68.9%)

32 (31.1%)

45 (73.8%)

16 (26.2%)

0.510

Portal vein invasion

Absent

VP1-2

VP3

VP4

9 (8.7%)

5 (4.9%)

19 (18.4%)

70 (68.0%)

4 (6.6%)

5 (8.2%)

9 (14.8%)

43 (70.4%)

0.882

Venous invasion

Absent

Present

76 (73.8%)

27 (26.2%)

50 (82%)

11 (18%)

0.230

Extrahepatic spread

Absent

Present

71 (68.9%)

32 (31.1%)

41 (67.2%)

20 (32.8%)

0.819

Tumor number

Single

Multiple

39 (37.9%)

64 (62.1%)

25 (41%)

36 (59%)

0.692

AFP, ng/ml(Mean)

≤ 400

> 400

33 (32.0%)

70 (68.0%)

26 (42.6%)

35 (57.4%)

0.172

High-risk type

VP4

TO 50%

Both

54 (52.4%)

33 (32.1%)

16 (15.5%)

31 (50.8%)

18 (29.5%)

12 (19.7%)

0.802

PD-1 inhibition agent

Camrelizumab

Tislelizumab

Sintilimab

62 (60.2%)

26 (25.2%)

15 (14.6%)

32 (52.5%)

20 (32.8%)

9 (14.7%)

0.694

ALBI grade

III

54 (52.4%)

47 (45.7%)

2 (1.9%)

25 (41.0%)

33 (54.1%)

3 (4.9%)

0.257

Laboratory tests

TBil, µmol/L (Mean, SD)

Albumin, g/L (Mean, SD)

Platelet, ×109/L (Mean, SD)

WBC, ×109/L (Mean, SD)

PT, seconds (Mean, SD)

Creatinine, µmol/L (Mean, SD)

ALT, IU/L (Mean, SD)

AST, IU/L (Mean, SD)

21.4, 12.3

38.4, 4.2

180.6, 78.6

6.0, 1.8

12.1, 1.1

65.5, 12.4

89.4, 55.9

58.1, 39.9

23.4, 14.4

39.3, 6.6

192.9, 86.6

6.4, 2.8

12.1, 1.1

75.0, 85.7

77.7, 38.6

49.9, 28.4

0.473

0.440

0.479

0.469

0.991

0.340

0.713

0.603

Abbreviations:

APF, α-fetoprotein; ALBI, albumin-bilirubin; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; PCT, procalcitonin; IQR, interquartile range; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBil, total bilirubin; PT, prothrombin time; WBC, white blood cells